New Eye Drop, Tryptyr, Demonstrates Significant Tear Production Increase in Dry eye Disease Study
Table of Contents
Acoltremon ophthalmic solution 0.003%, marketed as Tryptyr, led to a substantial 147% increase in tear production and a 72% increase in lipid concentration in patients with dry eye disease, according to phase 3b study results presented at academy 2025 in Boston on October 8-11, 2025. The findings suggest a promising new avenue for treating the widespread condition, which affects millions globally.
Restoring the Tear Film: How Tryptyr Works
Tryptyr functions by stimulating TRPM8 receptors, activating the trigeminal nerve, and ultimately boosting activity within the lacrimal functional unit – the system responsible for tear production. This mechanism aims to address not just tear volume, but also the quality of tears, which is often compromised in dry eye disease.
Study Details and Key Findings
Researchers conducted a study involving 41 adults diagnosed with dry eye disease. baseline measurements of the central tear meniscus height were taken in the left eye using Optical Coherence Tomography (OCT), while basal tears were collected from the right eye.Following the instillation of a single drop of Tryptyr in each eye,measurements were repeated after just three minutes.
“What they found was a 147% increase in tear production as measured by OCT,” explained a lead researcher. Tear meniscus height increased from an average of 343 µm at baseline to 847 µm post-instillation in 34 subjects. Furthermore, total tear lipids increased from 128 ng/mL to 221 ng/mL, representing a 72% increase. This lipid increase is especially significant, as it indicates an enhancement in the overall composition of the tear film.
The Shift Towards Non-Invasive Measurement
The study’s reliance on OCT for measuring tear volume was highlighted by Cory Lappin, OD, MS, FAAO, founder of The Dry Eye Center of Ohio. “I don’t use Schirmer testing,” Lappin stated. “It causes reflex tearing. I want noninvasive measurements.I use tear meniscus height in my clinic. I want to look at the patient’s tear production without me touching the eye.” Lappin emphasized the importance of this noninvasive data, particularly when combined with the lipid concentration results, suggesting a more complete picture of tear film health.
Twice-Daily Dosing and Mild Side Effects
Tryptyr is administered twice daily. while the treatment demonstrated significant efficacy, approximately 39% of patients reported mild instillation site burning and stinging.Researchers noted this side effect is consistent with the drug’s mechanism of action. “It tickles the nerve endings,” one researcher explained. “It stimulates the nerve endings to increase natural tear production. if you’re stimulating nerve endings, you’re going to probably feel a little sensation.”
Clinical Adoption and Future Outlook
Despite the mild side effects, clinicians are optimistic about Tryptyr’s potential. A researcher involved in the study indicated they are already prescribing the medication to the majority of thier patients, asking, “In what patient would I not want to increase natural tear production? Their basal tears have all of the healthy stuff.” Lappin echoed this sentiment, adding, “Almost all of your dry eye patients would get a benefit from this.”
For more information, Cory Lappin can be reached at [email protected]; on Instagram @cory.lappin; and on LinkedIn at cory Lappin, OD, MS, FAAO. nate Lighthizer can be contacted at [email protected].
Source: Lighthizer N, et al. Acoltremon 0.003% leads to a statistically significant increase in tear volume and tear total lipid concentration: Phase 3b study results. Presented at: Academy 2025; Oct. 8-11, 2025; Boston.
Disclosures: Lappin reports consulting for Alcon. Lighthizer reports having a financial relationship with Alcon.
